HIV-associated lymphoma: promising new results, but with toxicity.
Treatment of HIV-associated non-Hodgkin lymphoma with rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide resulted in high complete remission and 2-year failure free and overall survival rates but a high rate of infection.